Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bugusan
- Development stage
- Phase 2
- Lead developer
- Taichung Veterans General Hospital
- Administration
- Oral
01
Overview
Bugusan (BGS) is an investigational traditional Chinese medicine (TCM) herbal formula evaluated for the treatment of postmenopausal osteoporosis. Developed and studied by Taichung Veterans General Hospital, Bugusan is designed to regulate bone biomarkers and improve bone mineral density in postmenopausal women. It was evaluated in a Phase 2 randomized, double-blind, placebo-controlled clinical trial (NCT00202956) to assess its safety, tolerability, and effects on bone biomarkers.
- Other names
- 補骨散
Beyond the preview
Go deeper on Bugusan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bugusan.